Compensated HBV-related Cirrhosis
Conditions
Interventions
A:Nucleoside antiviral drugs+A formula particles
B:Nucleoside antiviral drugs+B formula particles
C:Nucleoside antiviral drugs+ B granule simulated agent
Sponsors
Beijing University of Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: The case may be included if meeting the following conditions: 1. To be confirmed by the Diagnostic criteria for compensated HBV-related liver cirrhosis; 2. According to the Standards of syndrome differentiation of qi deficiency, qi stagnation and blood stasis; 3. Serum total bilirubin in the normal high limit within a factor of 3; 4. HBV-DNA is negative after the treatment of nucleoside antiviral drugs(<=500 copies/ml); 5. Between the ages of 18-65 years (including 18 and 65 years old participants); 6. Having not been taking any Chinese medicine herbs 2 weeks before enrollment; 7. Junior high school and higher education levels; 8. Signed informed consent.
Exclusion criteria
Exclusion criteria: The case should be excluded if meeting any of the following conditions: 1. Accompanied with other types of cirrhosis; 2. Associated with other types of hepatitis virus infection; 3. HCC tendencies (AFP >=400 ug/L more than one month, Or >=200 ug/L for 2 months, Exclude pregnancy, embryonic gonads cancer and active liver disease; Concurrent liver cancer imaging characteristic footprint); 4. Accompanied with a clear diagnosis of cardiovascular system, respiratory system, urinary system, endocrine and blood disorders and malignancies in patients with severe primary; 5. Concurrent patients with serious; 6. Using of interferon within 24weeks before enrollment; 7. Associated with mental illness; 8. Breastfeeding or pregnant women; 9. Non-Chinese nationality.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes of TCM symptom Scores;Score Changes of Chronic Liver Disease Questionnai; | — |
Secondary
| Measure | Time frame |
|---|---|
| Score Changes of Fatigue Self-assessment Scale;Liver Elasticity Based on Fibroscan;The Shape and Size of Liver and Spleen by Abdomina;Blood Flow of Portal Vein;Routine blood test;Liver function;Coagulation items;HA, PCIII, LN, IV-C; | — |
Countries
China
Contacts
Public ContactTian-fang WANG
Beijing University of Chinese Medicine
Outcome results
None listed